-
公开(公告)号:EP1490110B1
公开(公告)日:2012-06-13
申请号:EP03755325.2
申请日:2003-03-13
发明人: VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
IPC分类号: C07K16/28 , A61K39/395 , A61K47/48 , A61P17/06 , A61P35/00 , A61P13/12 , A61P11/00 , A61P1/16 , G01N33/577 , C12N15/13 , C12N5/20
CPC分类号: C07K16/2839 , A61K47/48507 , A61K47/48561 , A61K47/48623 , A61K47/68 , A61K47/6835 , A61K47/6849 , A61K47/6851 , A61K47/6865 , A61K51/1027 , A61K51/1066 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57492 , G01N33/6893 , G01N2333/70546 , G01N2800/085 , G01N2800/205
摘要: A monoclonal antibody or an antigen binding fragment thereof that (a) specifically binds to ±v²6 but does not bind other av integrins; and (b) does not inhibit the binding of ²6 to latency associated peptide (LAP) with an IC50 value lower than that of 10D5. Said monoclonal antibody, wherein the antibody comprises a) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6. 2A1 (ATCC accession number PTA-3896) or b) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.2E5 (ATCC accession number PTA-3897). The disclosure also relates to uses of same and to compositions comprising same.
摘要翻译: (a)特异性结合±v26但不结合其他av整合素的单克隆抗体或其抗原结合片段; 和(b)不抑制结合26与潜伏相关肽(LAP)的结合,IC 50值低于10D5。 所述单克隆抗体,其中所述抗体包含a)与由杂交瘤6 2A1(ATCC登录号PTA-3896)产生的抗体相同的重链和轻链多肽序列或b)与所产生的抗体相同的重链和轻链多肽序列 通过杂交瘤6.2E5(ATCC登录号PTA-3897)。 本公开还涉及其用途和包含其的组合物。
-
公开(公告)号:EP1490110A2
公开(公告)日:2004-12-29
申请号:EP03755325.2
申请日:2003-03-13
发明人: VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
IPC分类号: A61K39/395 , C07K16/28 , C12N5/12
CPC分类号: C07K16/2839 , A61K47/48507 , A61K47/48561 , A61K47/48623 , A61K47/68 , A61K47/6835 , A61K47/6849 , A61K47/6851 , A61K47/6865 , A61K51/1027 , A61K51/1066 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57492 , G01N33/6893 , G01N2333/70546 , G01N2800/085 , G01N2800/205
摘要: A monoclonal antibody or an antigen binding fragment thereof that (a) specifically binds to ±v²6 but does not bind other av integrins; and (b) does not inhibit the binding of ²6 to latency associated peptide (LAP) with an IC50 value lower than that of 10D5. Said monoclonal antibody, wherein the antibody comprises a) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6. 2A1 (ATCC accession number PTA-3896) or b) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.2E5 (ATCC accession number PTA-3897). The disclosure also relates to uses of same and to compositions comprising same.
摘要翻译: 与αvβ6特异性结合的单克隆抗体。 还包括使用这些抗体治疗患有或有风险患有αvβ6介导的疾病或诊断αvβ6介导的疾病的哺乳动物的方法。
-
公开(公告)号:EP2524060A1
公开(公告)日:2012-11-21
申请号:EP11732315.4
申请日:2011-01-11
申请人: Biogen Idec MA Inc.
CPC分类号: G01N33/56983 , G01N2333/025 , G01N2469/20 , G01N2800/50
摘要: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
摘要翻译: 本公开涉及用于分析样品存在JC病毒抗体的方法和试剂。 公开了一种方法,其包括从受试者(例如血浆,血清,血液,尿液或脑脊液)获得生物样品,在适合于JCV结合的条件下使样品与高度纯化的病毒样颗粒(HPVLP)接触 样品中的抗体与HPVLP的检测,并检测JCV抗体在样品中与HPVLP结合的水平。 在一个实施方案中,确定受试样品中抗JCV抗体的水平提供了鉴定受试者中PML风险的方法。
-
公开(公告)号:EP1920065A2
公开(公告)日:2008-05-14
申请号:EP06774580.2
申请日:2006-07-10
申请人: Biogen Idec MA Inc.
发明人: VIOLETTE, Shelia , KOOPMAN, Louise, A. , SIMON, Kenneth, J. , WEINREB, Paul, H. , VAN VLIJMEN, Herman , SALDANHA, Jose , LUGOVSKOY, Alexey, A.
IPC分类号: C12P21/08 , C07K16/00 , A61K39/395 , G01N33/53 , G01N33/574 , C12P21/04 , C07H21/04
CPC分类号: C07K16/2839 , A61K2039/505 , A61K2039/545 , C07K16/30 , C07K2317/24 , C07K2317/41 , C07K2317/567 , C07K2317/76 , C07K2317/77 , G01N33/57407 , G01N33/57492 , G01N33/6893 , G01N2333/70546 , G01N2800/085 , G01N2800/12 , G01N2800/20 , G01N2800/347 , Y10S424/80 , Y10S424/801
摘要: The present invention is in the fields of cell biology, immunology and oncology. Specifically, the invention relates to humanized antibodies that recognizes v 6 integrins which comprises a variable region of nonhuman origin and at least -a portion of an immunoglobulin of human origin. The invention also relates to processes for their preparation, to pharmaceutical compositions comprising them and to methods of treating various diseases by administering humanized anti- v 6 antibodies. The invention also relates to the identification of differential expression of the integrin ±v²6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ±v²6.
-
-
-